Think your device won’t get payer traction because it’s outside the “big three”? This article breaks down how MedTech companies targeting niche patient populations can still win with U.S. payers by aligning with quality metrics, cost savings, and equity priorities.
One study rarely unlocks full payer coverage. Learn why U.S. market access requires a portfolio of evidence, strategic sequencing, and payer-specific insights.
Why do better technologies struggle for reimbursement while outdated ones thrive? Discover the hidden bias in payer decision-making—and why second movers in MedTech face steeper evidence hurdles than the first.